Bl-c Kit
NDC Package 76420-892-01
Package Information
Bl-c Kit (betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine) kits is iodixanol injection is indicated in for:. This formulation utilizes a kit delivery system. Marketed by Asclemed Usa, Inc., this product is identified by NDC 76420-892.
Identification & Billing
- RxCUI: 1737566 - lidocaine HCl 1 % in 5 ML Injection
- RxCUI: 1737566 - 5 ML lidocaine hydrochloride 10 MG/ML Injection
- RxCUI: 1737566 - lidocaine HCl 1 % per 5 ML Injection
- RxCUI: 1737566 - lidocaine HCl 50 MG per 5 ML Injection
- RxCUI: 578803 - betamethasone sodium phosphate / betamethasone acetate 6 MG/ML Injectable Suspension
Clinical Specifications
- Infiltration - Administration that results in substances passing into tissue spaces or into cells.
- Intra-articular - Administration within a joint.
- Intralesional - Administration within or introduced directly into a localized lesion.
- Intramuscular - Administration within a muscle.
- Intravascular - Administration within a vessel or vessels.
- Perineural - Administration surrounding a nerve or nerves.
- Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Regulatory & Marketing
Hierarchy Structure
- 76420 - Asclemed Usa, Inc.
- 76420-892 - Bl-c Kit
- 76420-892-01 - 1 KIT in 1 CARTON * 10 VIAL, SINGLE-DOSE in 1 CARTON (55150-162-05) / 5 mL in 1 VIAL, SINGLE-DOSE * .9 mL in 1 PACKET (67777-419-02) * 5 mL in 1 POUCH * 1 VIAL, MULTI-DOSE in 1 CARTON (0517-0720-01) / 5 mL in 1 VIAL, MULTI-DOSE * 10 BOTTLE, PLASTIC in 1 BOX (65219-383-05) / 50 mL in 1 BOTTLE, PLASTIC
- 76420-892 - Bl-c Kit
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 76420-892-01 identifies a specific commercial package of 1 kit in 1 carton * 10 vial, single-dose in 1 carton (55150-162-05) / 5 ml in 1 vial, single-dose * .9 ml in 1 packet (67777-419-02) * 5 ml in 1 pouch * 1 vial, multi-dose in 1 carton (0517-0720-01) / 5 ml in 1 vial, multi-dose * 10 bottle, plastic in 1 box (65219-383-05) / 50 ml in 1 bottle, plastic of Bl-c Kit, a human prescription drug labeled by Asclemed Usa, Inc.. This kit is formulated for infiltration; intra-articular; intralesional; intramuscular; intravascular; perineural; topical use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Asclemed Usa, Inc. on December 31, 2024. The current certification is valid through December 31, 2026.
How is this Asclemed Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 76420089201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
